There is no group anywhere in the world working harder or more effectively at the leading edge of the fight to detect and prevent Lyme disease than the one led by VCU School of Medicine's Richard Marconi, Ph.D. His team is exploring and developing solutions to counteract the growing negative health outcomes related to the continent’s steady increase in tick population.

In 2016, a novel, highly effective vaccine called Vanguard crLyme (Zoetis) that the team developed for dogs went to market. CrLyme is now the most widely used canine Lyme disease vaccine in North America. “The canine vaccine has taken the veterinary market by storm,” said Magdalena Morgan, Ph.D., director of licensing at VCU Tech Transfer and Ventures in the published story.